Clinical trial

Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated…

NCT00289757 · GlaxoSmithKline, Industry · Completed

Key facts

NCT number NCT00289757
Title Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine, Injected According to 0, 6-month Schedule
Official title Double-blind, Randomized Study to Evaluate the Immunogenicity and Reactogenicity of Three Different Lots of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Containing 1440 EL.U of Antigen Per mL and Injected According to a 0, 6 Month Schedule in Healthy Adult Subjects
Lead sponsor GlaxoSmithKline, Industry
Status Completed
Phase Phase 4
Study type Interventional
Conditions Hepatitis A
Intervention type Biological
Interventions Havrix™
Enrollment 78
Start date Jan 1, 2004
Primary completion Mar 1, 2013
Completion Mar 1, 2013
First posted Feb 10, 2006
Last update posted Jul 23, 2018
Countries Belgium

At a glance

  • 1–9 Study sites
  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies